Work

Efficacy Results of a Trial of a Herpes Simplex Vaccine

Year: 2020

Type: article

Abstract: Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not observed in men or HSV-1 seropositive women.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/zd06-bd20

Authors: Morrow, Rhoda L. Ashley, Heineman, Thomas C., Stokes-Riner, Abbie, Gorfinkel, Iris, Belshe, Robert B., Stapleton, Jack T., Leone, Peter A., Levin, Myron J., Bernstein, David I., Deal, Carolyn D., Dubin, Gary, Ewell, Marian G., Schulte, Joann M., Wald, Anna

Language: English

Topic: Herpesvirus Infections and Treatments

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Zalicus, H. Lundbeck A/S, Abbott Diagnostics, National Institute of Allergy and Infectious Diseases

Award: G1863689864

OpenAlex ID: W4299511726

FWCI:

Cites:

Cited by:

Related to: 10